Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06060405
Title Durvalumab and Oleclumab in Resectable PDAC (DORA)
Acronym DORA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.